Relationship between antithrombin-in value with acute coronary syndrome and preprocedural TIMI flow grade

National Medical Journal of China

Volumn 92, Issue 12, 2012, Pages 831-834

  Hong, Xia ^a   Shan, Pei Ren ^a   Hu, Long ^a   Huang, Zhou Qing ^a   Wu, Gao Jun ^a   Xiao, Fang Yi ^a   Huang, Wei Jian ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antithrombin M; Coronary artery disease; Pulsatile flow

Indexed keywords

ANTITHROMBIN III;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THROMBOLYSIS IN MYOCARDIAL INFARCTION FLOW; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART INFARCTION; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; ANGINA, UNSTABLE; ANTITHROMBIN III; CASE-CONTROL STUDIES; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES;

EID: 84868267947     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.12.012     Document Type: Article

References (16)

1. Cannon C P, Battler A, Brindis R G, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol, 2001, 38: 2114-2130.
2. Vancraeynest D, Pasquet A, Roelants V, et al. Imaging the vulnerable plaque. J Am Coll Cardiol, 2011, 57: 1961-1979.
3. Undas A, Szuldrzyński K, Brummel-Ziedins K E, et al. Systemic blood coagulation activation in acute coronary syndromes. Blood, 2009, 113: 2070-2078.
4. Ieko M, Naito S, Yoshida M, et al. Plasma soluble fibrin monomer complex as a marker of coronary thrombotic events in patients with acute myocardial infarction. Tohoku J Exp Med, 2009, 219: 25-31.
5. Brummel-Ziedins K, Undas A, Orfeo T, et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost, 2008, 6: 104-110.
6. Moyssakis I, Vlahodimitris I E, Kanakis M A, et al. Behavior of coagulation factors and normal inhibitors of coagulation during the acute phase of myocardial infarction. Blood Coagul Fibrinolysis, 2010, 21: 670-673.
7. Pu J, Shan P, Ding S, et al. Gender differences in epicardial and tissue-level reperfusion in patients undergoing primary angioplasty for acute myocardial infarction. Atherosclerosis, 2011, 215: 203-208.
8. 2006, 86: 1091-1092.
9. Schedin-Weiss S, Richard B, Hjelm R, et al. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry, 2008, 47: 13610-13619.
10. Tu C M, Hsueq C H, Chu K M, et al. Simultaneous thromboses of double coronary arteries in a young male with antithrombin III deficiency. Am J Emerg Med, 2009, 27: 1169. e3-e6.
11. Meng R, Li Z Y, Ji X, et al. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clin Neurol Neurosurq, 2011, 113: 380-386.
12. Thompson S G, Fechtrup C, Squire E, et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vase Biol, 1996, 16: 357-362.
13. Stone G W, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction; analysis from the primary angioplasty in myocardial infarction trials. Circulation, 2001, 104: 636-641.
14. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol, 2004, 43: 1363-1367.
15. Pelkonen K M, Wartiovaara-Kautto U, Nieminen M S, et al. Low normal level of protein C or of antithrombin increases risk for recurrent cardiovascular events. Blood Coagul Fibrinolysis, 2005, 16: 275-280.
16. Turker Y, Dogan A, Ozaydin M, et al. Association of thrombotic and fibrinolytic factors with severity of culprit lesion in patients with acute coronary syndromes without ST elevation. South Med J, 2010, 103: 289-294.